Differences in acquired immune deficiency syndrome treatment and evaluation strategies between Chinese and Western Medicine  by Zhibin, Liu et al.
TOPIC
JTCM |www. journaltcm. com December 15, 2015 |Volume 35 | Issue 6 |
Online Submissions: http://www.journaltcm.com J Tradit Chin Med 2015 December 15; 35(6): 718-722
info@journaltcm.com ISSN 0255-2922
© 2015 JTCM. All rights reserved.
REVIEW
Differences in acquired immune deficiency syndrome treatment
and evaluation strategies between Chinese andWesternMedicine
Liu Zhibin, Li Xia, Yang Jiping, Xu Liran, Guo Huijun
aa
Liu Zhibin, Xu Liran, Guo Huijun, Department of the Ac-
quired Immune Deficiency Syndrome Treatment and Re-
search Center, the First Affiliated Hospital of Henan Universi-
ty of Traditional Chinese Medicine, Zhengzhou 450000, Chi-
na; Department of Cellular Immunology Lab, Key Laborato-
ry of Viral Diseases Prevention and Treatment of Traditional
Chinese Medicine of Henan Province, Zhengzhou 450000,
China
Li Xia, Department of Neurology, Baoji City Chinese Medi-
cine Hospital, Baoji 721000, China
Yang Jiping, Department of the Acquired Immune Deficien-
cy Syndrome Treatment and Research Center, the First Affili-
ated Hospital of Henan University of Traditional Chinese
Medicine, Zhengzhou 450000, China
Supported by the National Special Science & Technology
Program on Major Infectious Diseases (No.
2012ZX10005010-001, No.2013ZX10005001-001); and
Henan Province Basic and Advanced Technology Research
Project (No.152300410165), and Henan Province Colleges
and Universities Key Youth Teachers Scheme (No.
2013GGJS-095)
Correspondence to: Prof. Xu Liran, Department of the Ac-
quired Immune Deficiency Syndrome Treatment and Re-
search Center, the First Affiliated Hospital of Henan Universi-
ty of Traditional Chinese Medicine, Zhengzhou 450000, Chi-
na; Department of Cellular Immunology Lab, Key Laborato-
ry of Viral Diseases Prevention and Treatment of Traditional
Chinese Medicine of Henan Province, Zhengzhou 450000,
China. drlzbcn@163.com; and Deputy Chief-Physician Li
Xia, Department of Neurology, Baoji City Chinese Medicine
Hospital, Baoji 721000, China. 13503829273@163.com
Telephone: +86-371-66264858
Accepted: August 20, 2015
Abstract
Complementary and alternative medicine, includ-
ing Chinese medicine (CM), has been used to treat
acquired immune deficiency syndrome (AIDS) for
almost 30 years. We aimed to compare the main dif-
ferences between AIDS treatment and evaluation
strategies between CM and Western Medicine
(WM), and analyze advantages and disadvantages.
The characteristics of integrative medicine (IM),
based on CM and WM, include a patient-centered
mode of medicine based on evidence. IM focuses
on complex intervention and management with
systemic and individual treatment. The evaluation
indexes of IM might consist of objective indicators
and subjective indexes. IM might be a more valu-
able method for treating AIDS in the future instead
ofWM or CM alone.
© 2015 JTCM. All rights reserved.
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INTRUDUCTION
Acquired immune deficiency syndrome (AIDS) is a
communicable disease that was recognized in the early
1980s. AIDS is caused by human immunodeficiency vi-
rus (HIV) infection. There are limited therapeutic op-
tions for AIDS, although combination antiretroviral
therapy (cART) has drastically reduced HIV-related
morbidity and mortality.1
Complementary and alternative medicine (CAM) is a
popular alternative to Western Medicine (WM) or con-
ventional medicine. CAM use among people living
with HIV is becoming increasingly widespread.2 Chi-
nese medicine (CM), a type of CAM, has been used to
treat AIDS for 30 years, and can reduce plasma HIV vi-
ral loads,3 increase CD4 + T cell counts,4 ameliorate
symptoms and signs,5 reduce opportunistic infections,6
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improve patient quality of life (QOL),7 and counteract
the effects of anti-retroviral drugs.8
Nevertheless, the role of CM in the treatment of HIV/
AIDS has not been widely recognized by some research-
ers and HIV patients. Therefore, to help more people
understand and use CM for AIDS treatment, we
aimed to compare the main differences in philosophi-
cal principles between CM and WM for AIDS treat-
ment. We hope that additional discussions and re-
search will result from this review.
BASIC DIFFERENCES BETWEEN
CHINESEMEDICINE ANDWESTERN
MEDICINE
In China, CM has a long history of use and a pro-
found cultural background. The philosophical founda-
tion that explains diseases or patient health is the main
difference between CM and WM.9 Chinese medicine
practitioners (CMPs) believe that the human body is
an organic whole. In CM, syndrome differentiation
and the holistic view are the base that CMPs use to
treat diseases or evaluate interventions.
According to CM theory, sick patients have an aggre-
gate of abnormal symptoms, signs, pulse, and tongue
picture caused by basic pathological factors (i.e. abnor-
mal status and outcomes of Yin-Yang, Qi-Xue,
Han-Re, or Xu-Shi). CM emphasizes the comprehen-
sive effects and subjective experience from disordered
pathological factors. Therefore, when CMPs give treat-
ments to their patients, they often focus on adjusting
the balance of Yin and Yang. CMPs also focus on the
harmonization of internal pathophysiological function
and environmental changes of patients through CM
methods combined with humanism and psychological
counseling. CM emphasizes integrative and individual
treatment, which results in patient-centered medicine.
WM theory is mainly based on human structures or
anatomy. Western Medicine practitioners (WMPs) con-
sider the human body to be composed of several dis-
tinct parts. Sick patients have abnormalities in behav-
ior, physiological function, mental and spiritual status,
structures, or laboratory results caused by certain
pathogens or disease states. Therefore, WMPs often fo-
cus on eliminating or removing the pathogen for their
therapy goals. WM emphasizes illness treatment,
which results in disease-centered medicine.
The two medical systems are not entirely different, and
some similarities between CM and WM exist aside
from the philosophical differences. The ultimate goal
of each system is to promote health, although they
use different methods. Some important ideas and
technological methods for treating and preventing dis-
ease are mutually accepted between the two medical
systems. More doctors have begun to practice integra-
tive medicine (IM), which combines elements of
WM and CM.
ADVANTAGES AND SHORTCOMINGS
OF AIDSTREATMENTWITH CMOR
WM
Because AIDS was only discovered in the 1980s, it was
not documented in any ancient Chinese medical litera-
ture. CMPs knew little about treating AIDS with CM
because there was no basic or clinical research using
CM methods. In 2004, the State Administration of Tra-
ditional Chinese Medicine of P.R. China started a pilot
program for the use of CM to treat AIDS patients in
conjunction with anti-retroviral drugs. Additional re-
search projects for AIDS National science foundation,
National 973 programs, National special science and
technology program on major infectious diseases, and
National 863 projects were funded by the government
of China.10
Review articles on using CM to treat AIDS11,12 describe
some advantages that CM has in AIDS treatment.
First, there are thousands of Chinese herbs13 and some
have demonstrated inhibitory activity against HIV rep-
lication.14 These herbs provide potential sources for re-
search and future treatment regimens. Furthermore,
the cost of CM is much lower than WM,15 which is im-
portant in developing countries. CM may have fewer
and less severe side effects than conventional pharmaco-
logical drugs.16 Some CMs have been shown to exert fa-
vorable immune regulation effects,17 and could be used
to promote immune reconstruction in concert with
cART. Early treatment with CM could slow the pro-
gression of AIDS.18
The usage of CM in AIDS treatment also has some
problems. The complexity of CM is not widely charac-
terized, especially in scientific research. There are also
no generally acknowledged evaluation indexes used for
CM in AIDS treatment. These problems slow the pro-
motion of CM among doctors and patients. Therefore,
potential beneficial effects need to be confirmed in
large, evidence-based, well-designed, and controlled
studies.19 Formulating recognized evaluation indexes
would also help standardize the effects ofCMonAIDS.
AIDS develops when the immune system is gradually
weakened after infection by HIV. The weakened im-
mune system leaves the body vulnerable to a variety of
life-threatening cancers and opportunistic infections.
Therefore, WM treatment for AIDS mainly focuses on
prevention of viral infection, inhibition of virus replica-
tion, and eradication of the virus. This is contrasted to
other therapies that attempt to improve the immune
function directly. Generally, HIV replication can be
suppressed by cART, but HIV cannot be completely
eradicated.20 AIDS patients have a persistent HIV reser-
voir,21 and the insufficient immunologic response is re-
lated to higher mortality22 even in cART patients who
have suppressed HIV viral loads.23,24 There are other
shortcomings that hinder AIDS treatment by cART
such as adverse side effects,25 drug resistance,26 and high
cost.27 These problems compel doctors to occasionally
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use uncertain immune-modulators or alter the cART
strategy.
Therefore, if CM and WM can be combined, AIDS
might be more effectively treated. This integrative
method could include the advantages and exclude the
disadvantages of CM and WM to benefit AIDS pa-
tients.
ADVANTAGES AND SHORTCOMINGS
OF IM AIDSTREATMENT
IM is defined by the Consortium of Academic Health
Centers for Integrative Medicine as "the practice of
medicine that reaffirms the importance of the relation-
ship between practitioner and patient, focuses on the
whole person, is informed by evidence, and makes use
of all appropriate therapeutic approaches, healthcare
professionals, and disciplines to achieve optimal health
and healing."28 IM combines aspects of CAM and WM
and advocates a patient-centered medicine based on ev-
idence.
IM has been used in China, especially for patients' suf-
fering from chronic diseases, including AIDS. IM uses
complex management, and emphasizes systemic and in-
dividual treatment. The evaluation indexes used in IM
can be more complex and include objective indicators
and subjective indexes.
Integrative therapies cannot entirely replace cART be-
cause research must be conducted to evaluate interac-
tions between the herbs or supplements and cART,
drug safety, and treatment adherence. Nevertheless,
some research has demonstrated that IM can reduce
the side effects of cART,29 promote immune reconstitu-
tion with cART,30 improve QOL after cART,31 and ben-
efit long-term survival of AIDS patients without
life-long medication.32
There is still no cure for AIDS, and the prospect of an
effective HIV vaccine to contain the pandemic remains
uncertain. IM may an effective alternative to treating
AIDS.
EVALUATION INDICATORS OF IM
TREATMENTS FOR AIDS
If HIV infection is not detected and treated, the im-
mune system is weakened and AIDS develops. CD4+
T Cells, which are important to the regulation of hu-
moral and cellular immune function, decrease in AIDS
patients because of direct HIV cytotoxicity and indi-
rect apoptosis induction mechanisms.33 Therefore elimi-
nating, diminishing, or suppressing HIV load and im-
proving the immune system are the main goals for
WM. These results can be achieved with cART, which
can restore and preserve immunological function, pre-
vent opportunistic diseases, and reduce mortality.34
CD4+ T cell counts and plasma HIV viral loads are rec-
ommended as the main evaluation criteria by WHO
for AIDS therapy,35 and have been used in research,36
clinical practice,37 and drug screening.38
The mortality and morbidity of AIDS has been greatly
reduced by cART, and patient survival has increased.
Nevertheless, patients and doctors are not merely con-
tent with improving CD4+ T cell counts and suppress-
ing plasma HIV viral loads. Health is not only the ab-
sence of disease or illness, but also includes physical,
psychological, and social aspects. Disease evaluation
and clinical efficacy include biological indicators, and
comprehensive psychological, physiological, and social
information. Therefore, other indicators can be used to
evaluate a treatment or therapy aside, including
health-related QOL,39 dermatology life quality index,40
some symptoms and signs (e.g. fatigue,41 insomnia,42 de-
mentia,43 fever,44 diarrhea45), or mental and spiritual
changes.46 To some extent, changes other than cell
counts and HIV loads reflect the demands of the pa-
tients rather than HIV and the immune system as ulti-
mate goals of AIDS treatment.
CMPs always focus on the clinical subjective percep-
tion of AIDS patients. CMPs look at AIDS as the ag-
gregate results of abnormal symptoms, signs, pulse,
and tongue picture, which manifest as lower QOL,
complications, opportunistic infections, cART side-ef-
fects, lower CD4 + T cell counts, and higher HIV
loads. Therefore, CMPs make subjective decisions as
evaluation indicators in AIDS treatment when they be-
gin or change patient treatment strategies or conduct
research.47-49
In evaluating the effects of IM on AIDS treatment,
some indexes can be used including symptoms, signs,
health-related QOL, complications, side-effects of
cART, and drug resistance, in addition to HIV plasma
viral loads and CD4+ T cell counts.
CONCLUSIONS
AIDS is a worldwide public-health problem. The roles
of CAM in AIDS treatment have been recognized and
accepted by some patients. IM, which can bridge CM
and WM in China, could be a valuable method to con-
quering AIDS in the future.
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